medicalxpress.com
In a promising development for cancer prevention, glucagon-like peptide-1 receptor agonists (GLP-1 RAs), commonly used in diabetes management, have been linked to a reduced risk of early-onset colorectal cancer (EO-CRC) in patients under 50 with type 2 diabetes. These findings, presented at the recent American College of Gastroenterology annual meeting, indicate that GLP-1 RAs may play a role in cancer prevention strategies for younger patients with diabetes.
Led by Dr. Temitope Olasehinde from Case Western Reserve University, researchers examined data from approximately 1.8 million diabetic patients under age 50 who had no prior colorectal cancer diagnosis. The team used the TriNetX health research network to identify a group of 77,688 propensity-matched patients, comparing those who used GLP-1 RAs with those who did not. Their analysis showed a lower incidence of EO-CRC in the group taking GLP-1 RAs, with an incidence rate of 0.4% versus 0.7% in the non-GLP-1 RA group. Notably, patients with obesity who used GLP-1 RAs had a particularly reduced risk of developing EO-CRC compared to those with obesity who did not use these medications.
These findings suggest that GLP-1 RAs could potentially contribute to reducing cancer risk among diabetic patients, particularly those with obesity. Given the significant need for cancer prevention strategies tailored to younger patients with diabetes, this research may be an important step forward. However, the authors caution that further randomized controlled trials are necessary to confirm these results and explore the full preventive potential of GLP-1 RAs against colorectal cancer.
As early-onset colorectal cancer remains a critical area of concern, continued research into GLP-1 RAs could offer valuable insights into novel approaches for cancer prevention in at-risk younger adults managing diabetes.